Skip to main content
Premium Trial:

Request an Annual Quote

Saqqara, Cellular Genomics to Collaborate on Drug Design

NEW YORK, Oct. 6 (GenomeWeb News) - Saqqara Consultants will collaborate with Cellular Genomics on the development of structure-based drug design utilizing Saqqara's crystallization expertise, the firms announced today.


Terms of the agreement were not disclosed.


Carlsbad, Calif.-based Saqqara specializes in applying X-ray crystallography and molecular modeling to drug discovery programs. Branford, Conn.-based Cellular Genomics applied its chemical genetics platform to in-house drug discovery efforts, as well as to collaborations with pharma and biotech companies, including Affymetrix, Eli Lilly, and Pfizer. The firm recently raised $34.9 million in a Series C private financing.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.